Background: Type 2 diabetes mellitus (T2DM) is a progressive condition that often requires combination therapy for optimal control. Dapagliflozin offers complementary glycaemic, metabolic, and cardiovascular benefits when combined with other oral antidiabetic agents. This study aimed to assess healthcare professionals’ (HCPs) real-world experience with dapagliflozin-based regimens in Indian patients with T2DM, with a focus on glycaemic improvement, metabolic outcomes, and treatment tolerability.

Methods: A questionnaire-based observational survey was conducted among 401 HCPs across India, including endocrinologists, diabetologists, and general physicians. A structured 24-item questionnaire captured data on patient characteristics, glycaemic response, HbA1c and fasting blood glucose (FBG) improvement, cardiovascular and renal benefits, weight changes, lipid profile changes, adverse events, and discontinuation patterns based on the last 10 patients treated. Descriptive statistics were used, and results were expressed as percentages.

Results: Most HCPs reported that the majority of their managed patients were between 41 and 60 years of age, with overweight and obesity frequently observed. Dapagliflozin was frequently initiated in patients with HbA1c 8.1-9.0%, and 48.88% observed HbA1c target achievement in at least 9-10 patients. An HbA1c reduction of 1.1-1.5% and FBG improvement of 31-50 mg/dL were commonly reported. Dapagliflozin provided additional benefits, including blood pressure reduction, improvement in heart failure symptoms, slowed CKD progression, and favourable changes in lipid parameters. Weight loss of >2 kg over 3 months was frequently noted. Adverse events were minimal, with genital infections being the most common, and most HCPs (66.83%) reported no therapy discontinuation.